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2Abstract
Objective
To evaluate the contribution of clinical information and biomarkers to the prediction of cognitive
decline in newly diagnosed Parkinson’s disease (PD) patients.
Method
Cognitive performance (Montreal Cognitive Assessment (MoCA) score), demographic and clinical
data, and biomarkers (ApoE status, cerebrospinal fluid (CSF) and dopamine-transporter
(DAT) imaging results were evaluated in 390 newly diagnosed PD patients in the Parkinson’s
Progression Markers Initiative. Using i) change in MoCA score over two years, ii) MoCA scores
at year two follow-up, and iii) a diagnosis of cognitive impairment (combined MCI or dementia)
at two years as outcome measures, the predictive values of (i) baseline clinical variables and (ii)
separate or combined additions of ApoE status, DAT-imaging and CSF biomarkers were assessed.
In addition, a prediction model using logistic regression analysis was run. Bootstrap
analysis, 10-fold cross validation and cohort splitting were performed for model validation.
Results
In multivariate analyses, baseline age, University of Pennsylvania Smell Inventory Test
(UPSIT) score, CSF Aβ1-42/t-tau ratio and ApoE status were associated with change in 
MoCA score over time; and baseline age, MoCA and UPSIT scores, and CSF Aβ1-42/t-tau 
ratio with MoCA score at 2 years. Accuracy of prediction of cognitive impairment using age
alone (AUC 0.68, 95% CI 0.60-0.76) improved significantly by addition of clinical scores
(UPSIT, REM-Sleep Behavior Disorder-Screening Questionnaire (RBDSQ), Geriatric
Depression Scale and MDS-UPDRS motor scores; AUC 0.76, 95% CI 0.68-0.83), CSF variables
3(AUC 0.74, 95% CI 0.68-0.81), or DAT-imaging results (AUC 0.76, 95% CI 0.68-0.83)). In
combination, the five variables showing the most significant associations with cognitive
impairment (age, UPSIT, RBDSQ, CSF Aβ1-42 and caudate uptake on DAT-imaging) allowed 
prediction of cognitive impairment at 2 years with an AUC 0.80 (95% CI 0.74-0.87, p<0.001).
Conclusion
In early PD, the occurrence of cognitive impairment two years later can be predicted with good
accuracy using a combination of age, non-motor assessments, DAT-imaging and CSF
examination.
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Cumulative incidence of dementia in Parkinson’s disease (PD) is as high as 80% after 8 years
disease duration 1, and deterioration in cognition is a significant contributor to the
disability associated with PD 2;3. Mild cognitive impairment (PD-MCI) is a term used to denote
cognitive impairment falling short of dementia in PD 4, with current evidence suggesting that
almost all patients with PD-MCI will subsequently convert to dementia in the course of PD 4;5.
Early identification of those at risk of developing cognitive impairment in PD may help stratify
the early PD population for clinical trials and prognostic information, and improve
understanding the pathophysiology of cognitive decline in PD.
There are several possible mechanisms by which cognitive impairment develops in PD.
Pathological studies demonstrate that AD (-amyloid plaques and tau neurofibrillary tangles)
and PD pathology (cortical Lewy bodies) commonly coexist12. Dopaminergic deficits per se are
associated with cognitive impairment, as evidenced by the fact the administration of
levodopa early in the disease course can alleviate cognitive symptoms, especially the
frontal-executive type14, and that neuroimaging studies have shown relationships between
caudate and putamen dopamine transporter density and with prefrontal dysfunction in PD
patients15.
In terms of clinical predictors, age, male sex, education, lower baseline cognitive score, severity of
motor symptoms, hyposmia and REM-sleep behavior disorder (RBD) have all been suggested to
predict cognitive decline in PD6-9. Biomarker studies reported that dopamine depletion on DAT-
5imaging is associated with subsequent cognitive decline in PD10-13. A number of studies have also
examined the association of cognitive impairment in PD with CSF levels of α-synuclein, Aβ1-42, 
total tau (t-tau), phosphorylated tau 181p (p-tau), and Aβ1-42/t-tau ratio as well as ApoE4 
status 13;16;17. However, the results of previous studies have been conflicting on the
contribution of these CSF parameters for the prediction of cognitive impairment in PD18-22 and
to our knowledge no study has previously combined clinical, CSF and DAT imaging parameters
or calculated the predictive value of these variables for development of cognitive impairment
in PD. In this study we aimed to evaluate the extent to which the various clinical, imaging,
biomarker and genetic metrics can predict the development of cognitive impairment, both
individually, and in combination. Specifically, we hypothesized that adding CSF and DAT
imaging results to clinical assessments would significant contribute to prediction of cognitive
deterioration at 2 years.
Methods
The current study investigated clinical and biomarker predictors of cognitive decline in the
early stage of PD from the Parkinson’s Progression Marker Initiative (PPMI; http://www.ppmi-
info.org/wp-content/uploads/2013/02/PPMI-Protocol-AM5-Final-27Nov2012v6-2.pdf). The
PPMI is an ongoing, multicenter longitudinal study to assess progression of clinical features,
imaging and biomarkers of PD patients compared to healthy controls23. Assessments
comprise clinical evaluation of motor and non-motor features as well CSF examination and
ioflupane iodine-123 DAT SPECT (DATSCAN) imaging at baseline. The de-identified data is
made available to investigators. Baseline clinical and cognitive data 24 and the association of
6CSF Aβ1-42 with cognitive impairment at 2 years have previously been reported 13.
Participants
Only data from PD patients with 2 year follow up were included in this analysis. At baseline
participants were required to (1) have an asymmetric resting tremor or asymmetric
bradykinesia, or two of bradykinesia, resting tremor, and rigidity; (2) have a recent PD
diagnosis; (3) be untreated with medications for PD; and (4) have a dopamine transporter (DAT)
deficit on imaging. For comparison, we also analysed results in the HC group (n=178). The study
was approved by the Institutional Review Board at each site, and participants provided written
informed consent24. Data were downloaded on 1st April 2015.
Assessments included in this analysis
Outcomes: Cognitive decline was evaluated using (1) change in Montreal Cognitive Assessment
(MoCA), a scale for global cognitive abilities validated for use in PD25-27, from baseline to two-
year follow-up, (2) MoCA score at the 2-year assessment and (3) categorization as cognitively
impaired at 2 years. Cognitive tests that were performed and used to allow classification of
cognitive function were, (1) memory: Hopkins Verbal Learning Test—Revised (HVLT-R) 28; (2)
visuospatial function: Benton Judgment of Line Orientation29 15-item (split-half) version; (3)
processing speed-attention: Symbol-Digit Modalities Test (SDM)30; (4) executive function and
working memory: Letter-Number Sequencing (LNS) 31; and (5) semantic (animal) fluency32.
Individuals were categorized as having “Normal cognition”, “PD-MCI” or “Dementia”, according
to the PPMI protocol: PD-MCI was defined as scores on two or more of the HVLT Total Recall,
7HVLT Recognition Discrimination, Benton Judgment of Line Orientation, LNS, SFT, or SDM > 1.5
standard deviation below normal, and no functional impairment due to cognition impairment.
A diagnosis of dementia also required evidence of functional impairment.
Clinical variables included in the current study, as they have previously been reported to be
associated with cognitive decline in PD, included: age, sex, years of education, disease duration,
sense of smell assessed using the University of Pennsylvania Smell Identification Test (UPSIT)33,
RBD measured using the RBD Screening Questionnaire (RBDSQ)34, depression measured using the
15-item Geriatric Depression Scale (GDS) 35, PD severity measured using the MDS-UPDRS motor
score, and tremor-dominant, postural instability gait difficulty (PIGD) subtype, and
indeterminate motor subtypes36. For biomarker studies, we included DAT imaging data for
mean caudate and putaminal uptake relative to uptake in the occipital area, and asymmetry of
caudate and putaminal uptake (side with highest/side with lowest uptake) (http://www.ppmi-
info.org/study-design/research-documents-and-sops); Apo-E e4 status (e4 homozygous,
heterozygous, or negative ); and CSF results for α-synuclein (repeated for those with CSF 
hemoglobin<200ng/ml as the high α-synuclein content in blood may lead to high α-synuclein 
levels in traumatic taps), Aβ1-42, total (t-tau) and phosphorylated tau181 (p-tau), and total
protein (as described previously 16;23).
Statistical Analysis
Analyses were performed with data collected at baseline/screening (MoCA and DAT imaging)
and at 2-year follow up. MoCA change score was calculated as MoCA baseline score – MoCA 2-
year score. Variables were analysed for missing data. Comparisons between groups were made
8using Chi-Square tests, t-tests for normally distributed variables, and Mann-Whitney tests for
non-parametric data. We examined the residuals to ensure they fulfilled all linear regression
assumptions. The residuals were not negatively skewed when tested in the final model, checking
both graphically and using normality tests, while homoscedasticity and independence also
applied. Univariate and multivariate linear analyses with MoCA change scores between baseline
and two years assessment and with MoCA score at 2 years as dependent variables were
conducted using backwards linear regression analysis. Variables were entered as independent
variables if they had a univariate association with a p-value of less than 0.20 37;38. If
variables were highly correlated, the variable with the lower p-value was entered as
independent variable. MoCA scores at baseline were not included in multivariate linear
regression analysis to predict the change of MoCA score from baseline to 2 years to avoid
including them on both sides of regression equation39, but they were included in analysis with
MoCA scores at 2 years40 . Univariate logistic regression analysis was used to identify possible
risk factors for cognitive impairment (defined as either PD-MCI or dementia) at 2 years. We
used the Benjamini-Hochberg procedure41 controlling for a false discovery rate(FDR) of 0.05,
resulting in a significance level of p<0.0167 for this univariate comparison.
Several multivariate logistic regression models were then developed with cognitive
impairment at 2-year follow-up as dependent variable: using age only; then (a) age with
clinical variables; (b) age with DAT imaging results; (c) age with CSF biomarkers; and (d) age
with clinical, DAT imaging and CSF biomarkers. For these logistic regression models,
independent variables were included if they were not highly correlated (r>0.5) and were
significantly different between those with and those without cognitive impairment
9(p≤0.05) 42. For the model with combined clinical and biomarker variables, only independent
variables with a p-value of <0.005 were included to restrict the number of predictors for ease of
use in clinical practice and to avoid overfitting of the model 43;44. A bootstrap resampling
procedure with 1000 repetitions was applied to the final risk model. In order to confirm the
accuracy of prediction for internal validation, 10-fold cross-validation and cohort splitting were
used. Bootstrapping replicates the process of sample generation from an underlying population
by drawing samples with replacement from the original data set, which is of the same size as
the original data set, whereas in 10-fold cross-validation the data set is divided into k subsets,
and the holdout method is repeated k times. Each time, one of the k subsets is used as the test
set and the other k-1 subsets are put together to form a training set45. Moreover, we separated
the original dataset in development and validation samples, comprising 70% and 30% of the
original data set respectively (cohort splitting). Discrimination of the models was quantified via
an area under a receiver operating characteristic (ROC) curve;46 the predictive ability was
determined with Nagelkerke’s R2 index, and the calibration was tested with the Hosmer-
Lemeshow test for goodness of fit47. The logistic regression models were repeated and
presented with imputation of missing data in the independent variables using variable means.
Statistical analysis was carried out STATA 13.
To predict risk of individual patients, a risk model was constructed to calculate predicted risk in
the following way:
Patient’s risk of cognitive impairment at 2 years = exp(patient’s risk score) ÷ (1+exp(patient’s
risk score));
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where patient’s risk score = intercept + (bvariable 1×variable1) + (bvariable 2×variable2) +
(bvariable 3× variable3) + (bvariable4 ×variable4) + (bvariable5×variable5);
and bvariable1, bvariable2, bvariable3, bvariable4, and bvariable5 are the regression
coefficients.
Reference Range=exp(patient’s risk score +/- 1.96*Std.Error) ÷ (1+exp(patient’s risk score+/-
1.96*Std.Error))
Findings
393 subjects fulfilling PPMI criteria for newly diagnosis PD had 2-year follow-up. Three did not
have a baseline MoCA and were excluded. 318 had 2-year MoCA results available at the time of
data download, of whom 314 had undergone classification for cognitive impairment. There was
no significant difference in the tested variables between those with and without 2-year
cognitive follow-up data, except mean caudate asymmetry which was greater in those without
cognitive assessment at 2 years (p=0.02).
There were no missing values in age, gender, education years, disease duration, baseline MoCA
scores, UPSIT scores, MDS-UPDRS motor scores and motor subtype, two for GDS and 34 for
RBDSQ. Apo E status data was missing in 37 patients. No DAT imaging data were missing.
Baseline CSF data were missing in 10 patients for Aβ1-42 and α-synuclein, 12 patients for p-tau, 
14 patients for t-tau and 31 for total protein. We repeated analyses by imputing missing
predictor variable data with average means. These did not alter the overall results of any
analysis.
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Predictors of change in cognitive function over 2-year follow up
In multivariate analyses, change in MoCA scores from baseline to 2-year follow-up was
associated with age, UPSIT score, Apo E status, and CSF Aβ1-42/t-tau ratio (table 1). For 
Healthy Controls, change in MoCA score from baseline to 2-year follow-up was associated
with age, gender, and CSF Aβ1-42 (Table 1 Supplementary material). 
Predictors of cognitive function at 2 years follow up
In multivariate analyses, MoCA score at 2-years was associated with age, baseline MoCA and
UPSIT scores and CSF Aβ1-42/t-tau ratio (Table 1). For Healthy Controls, MoCA score at 2-years
was associated with age, gender, baseline MoCA score and CSF Aβ1-42. (Table 1
Supplementary material).
Prediction of classification of cognitive Impairment at 2 years follow up
Forty-nine participants with PD were classified as having PD-MCI at 2-year follow up, three
as demented and 262 judged as cognitive normal. Only two HC were classified as having
MCI and none as demented at two years and were not analysed further. At follow-up 233
of those without and 48 with cognitive impairment had been treated with antiparkinsonian
medication (p=0.47). Four patients in the group with cognitive impairment had been
started on medication for cognitive impairment. At baseline, participants with PD judged as
cognitively impaired (MCI or dementia) were older, had higher RBDSQ scores at baseline,
lower UPSIT scores, lower CSF Aβ1-42 and Aβ1-42/t-tau ratios, and lower mean caudate 
uptake and caudate and putaminal asymmetry (table 2).
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Using those clinical variables showing univariate association (p<0.05) with cognitive
Impairment at 2 years (age, MDS-UPDRS motor score, GDS, UPSIT and RBDSQ scores) as
independent variables in logistic regression analysis, prediction accuracy was greater than
for age alone (p=0.025; figure 1a). DAT imaging parameters with univariate association with
cognitive impairment (mean caudate uptake, caudate and putaminal asymmetry) also
increased the AUC over age alone (p=0.018; figure 1b), as did CSF Aβ1-42 (p=0.0195; figure 
1c). Combining the five variables most strongly associated with cognitive impairment in
univariate analysis, (age, UPSIT and RBDSQ scores, CSF Aβ1-42 and mean caudate uptake) 
gave an AUC of 0.80 (95% CI 0.74-0.87; p=0.0003 compared to age alone; figure 1d). All
risk models produced good discrimination and calibration, with the final risk model giving an
AUC 0.80, Nagelkerke’s R2 of 0.20 and acceptable goodness of fit (Hosmer-Lemeshow Chi-
Square 6.27; 8 df; p=0.62) in the final risk model. Whilst each model was significantly better
than age alone at predicting cognitive impairment at 2 years, there was no statistically
significant difference in AUCs between the models with Clinical variables, CSF and DAT imaging
parameters combined with age when they were compared in pairs. However, AUCs of both the
models with Clinical and with CSF parameters combined with age were statistically significant
different from the final model (p= 0.03 and p=0.02) and there was a trend for the model with
DAT imaging parameters (p=0.13; Supplementary Figure 1).
The results of the bootstrapped logistic regression analysis of the final model are given in table
3. Association of mean caudate uptake with cognitive impairment failed to reach significance
in this model (p=0.09) but removal of mean caudate uptake from the analysis did not change
the scores derived for the other factors.
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The results of the 10-fold cross-validation confirmed the final model, showing no statistically
significant difference in the performance of the final model between 10 different samples
(p=0.88); the results of the cohort splitting also showed no statistically significant difference in
the AUCs for the same model in the development and validation sample (Supplementary
Figures 2 and 3).
Using an example for the final model, a 70 year old patient with newly diagnosed PD who
has an UPSIT score of 22 and an RBDSQ score of 5 with a CSF Aβ1-42 of 399 pg/ml and a mean 
caudate uptake of 1.99 has a predicted risk of cognitive impairment at 2 years of 13% (7 – 18%).
If the patient was 50 years old, the predicted risk with these results would be 5% (1-9%). If the
70 year old patient had a CSF Aβ1-42 of 310pg/ml, an UPSIT score of 17, an RBDSQ score of 7 
and a mean caudate uptake of 1.79, it would be 34% (25-43%).
Interpretation
In this study we have identified clinical and biomarker predictors of cognitive impairment in the
first two years following initial diagnosis of PD. Early cognitive decline, a strong predictor of
development of dementia in PD, was associated with a number of clinical variables, whether
outcome at year 2 was change in MoCA scores, absolute MoCA scores, or classification of
cognitive impairment (MCI or dementia) based on investigator assessment and detailed
cognitive testing. Beside higher age, the strongest clinical predictors were reduced sense of
smell, the presence of REM sleep behavior disorder and, to a lesser degree, depression and
motor scores. There was evidence for a relationship between APOE genotype and MoCA
change score, similar to what has been reported previously in the general population and in
PD48;49. A significant association was also seen between MoCA change scores and lower CSF
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Aβ1-42/t-tau ratio. DAT imaging results, i.e. reduced mean caudate uptake and asymmetry and, 
to a lesser degree, lower putaminal asymmetry, were also predictive of cognitive impairment
after two years in multivariate analysis.
The prevalence of cognitive impairment in both the population and in patients with PD is
known to increase with advancing age50;51, and age was the strongest clinical predictor of
cognitive impairment in this analysis in patients and healthy controls. Although a trend was
seen towards cognitive impairment being associated with less formal education, which has
previously been reported to be a risk factor for cognitive deterioration in the general
population and PD50;52, this association failed to reach significance in the multivariate analyses;
male sex also did not further contribute to prediction of cognitive deterioration in participants
with PD, although this previously identified risk factor for cognitive decline6 was confirmed in
our healthy control population.
Patients with more severe motor symptoms and those with greater depression scores were
more likely to be classified as cognitively impaired, in line with previous reports of motor
severity and depression being predictors of cognitive deterioration in PD 6;51;53. The previously
postulated association of the PIGD subtype with worse cognition51;54;55 was not seen in this
early phase study, which may in part be due to instability of this categorization.
Some of the strongest associations with cognitive decline were seen with baseline UPSIT and
RBDSQ scores. Hyposmia has been reported as a risk marker for both PD56 and AD57 and has
previous been associated with cognitive decline in PD9;58. It has been postulated that sense of
smell reflects extrastriatal neurodegeneration in both AD and PD, and whilst the underlying
pathological basis for this unclear this may reflect early involvement of the olfactory bulb in
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both disorders 59-62. Similarly, RBD, even when assessed using a questionnaire (RBDSQ) rather
than a formal sleep study, was a useful predictor of cognitive impairment in this early disease
sample. Reduced and asymmetric DAT-tracer uptake particularly in the caudate was associated
with cognitive deterioration in line with previous studies which have implicated the caudate,
and to a lesser degree the putamen, in cognitive function in both health individuals 63 and
patients with PD64-67.
CSF Aβ1-42 results at baseline also contributed to predicting cognitive deterioration. CSF Aβ1-
42 level is a marker of CSF amyloid pathology of AD, inversely correlating to brain β-amyloid 
plaque load. Reduced CSF Aβ1-42 is a core feature of Alzheimer’s disease but is are also seen in 
other neurodegenerative disease and notably in Dementia with Lewy bodies and Parkinson’s
disease dementia, likely due to the deposition of both Parkinson’s and Alzheimer pathology in
the brain. 68. This study is not able to determine to what extent the underlying pathology of this
cognitive decline is concomitant Alzheimer’s versus Lewy Body pathology, but suggests that
amyloid deposition is an important contributor to development of cognitive impairment in early
PD. It is noteworthy that CSF t-tau was also associated with MoCA score at two years, reflecting
the contribution of neuronal loss in this neurodegenerative process. At least in AD studies levels
of CSF tau levels correlate more with measures of neurodegeneration (e.g. atrophy) and
cognitive decline than CSF Aβ1-42 level69. Previous studies examining the value of CSF
constituents as predictors of cognitive decline in PD have produced inconsistent results. In
some studies, lower levels of CSF Aβ1-42 without a contribution of p-tau or t-tau were reported 
18;20;70;71, whereas higher levels of CSF p-tau but not lower levels of Aβ1-42 were associated with 
cognitive decline in early PD in the DATATOP study21. Some studies also reported that higher α-
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synuclein predicted cognitive decline20;71 but the results from the DATATOP suggested this is
only seen in early disease19, whereas higher p-tau and p-tau/Aβ42 ratio in the same study were
associated with cognitive decline in more advanced disease suggesting different mechanisms
involved at these different disease stages21. In the present study CSF α-synuclein and p-tau 
levels, which have previously been reported to be significantly lower than in controls in this PD
population 16, were not helpful in predicting early cognitive deterioration in this population.
These differences between studies may reflect differences in sample sizes18;20, disease
stages18;20, variability in measurements of the different CSF proteins, or in assessments
methods between these studies, and highlight the need for improved standardization of CSF
protein measurements.
The main purpose of this analysis was to determine the value of clinical markers as well as
various widely available biomarkers at the time of diagnosis of PD in predicting the
development of cognitive impairment over two years. Clinical markers, particularly age, UPSIT
and RBDSQ, provided useful discriminative value over and above age alone. Similarly, addition
of CSF Aβ1-42, or caudate uptake and caudate and putaminal asymmetry on DAT imaging 
markers increased discriminative value of age for prediction of cognitive impairment, with
similar predictive values in all three models. Compared to age alone which has a predictive
value AUC of 0.68 (95% CI 0.60-0.76), a model taking into account both clinical variables and
biomarkers increased the AUC to 0.80 (95% CI 0.74-0.87). Therefore, combining these clinical
and biomarker variables may be most helpful in clinical practice and, importantly, in clinical
trials aiming to identify those at risk of cognitive decline. Thus, calculating a 5% risk with a
reference range of 1-9%, compared to a 13% (7-18%) or a 34% (25-43%) risk is likely to be
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clinically useful.
In the absence of pathological confirmation, the current data cannot determine the
pathological underpinning of early cognitive decline in PD, which is likely to be multifactorial.
Furthermore, the nigrostriatal dopaminergic deficit demonstrated on DAT imaging does not
necessarily reflect dopaminergic deficits in other brain areas. However, this analysis suggests
that the nigrostriatal deficit, which underlies the motor symptoms of PD, is not the primary
driver of cognitive changes seen at this early post-diagnostic stage.
Limitations of this study
This assessment only included the first two years post-diagnosis, with median duration since
diagnosis of 4 (IQR 2-8) months at baseline. Therefore, few patients had developed frank
dementia by clinical cognitive assessment. Whilst MCI is considered a pre-dementia phase, not
all patients will develop dementia. Nevertheless, previous studies have reported a very high
conversion rate of MCI to dementia in patients with PD with new diagnosis of MCI5. Our results
should therefore be considered in the context of predicting cognitive impairment rather than
dementia. In addition, classification of cognitive impairment was not usually performed at the
start of the study. However, even if MCI had been noted at inclusion, this may have reflected
this symptom already being present given the long pre-diagnostic phase of PD, as time of
diagnosis depends on many variables, including health-seeking behaviour and availability of
specialist access72. The changes in the main outcomes in the early phase of PD examined are
too small to distinguish those with slower or faster progression to clinical dementia, for which
longer follow-up will be required. Finally, the prediction formula should be further validated in
other samples and interpreted in the appropriate clinic context.
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However, strategies to identify which individuals with PD are at risk of developing cognitive
impairment may have prognostic implications for patients, and may allow for clinical trials to
prevent or slow the onset of cognitive decline with major implications for patients, families and
society. It is for instance unclear whether there are benefits of trialing ACHEI medications, with
proven benefit in PDD, at very early stages. Whilst considerably more work is required to
determine the pathological features underlying risk for cognitive impairment at this stage,
these results suggest that using clinical markers and currently available biomarkers it is possible
to define a population at high risk of cognitive decline who may benefit for interventions as well
as being the subject of future trials. Whilst these results need confirmation in further studies,
our results demonstrate that a simple algorithm combining age, presence of hyposmia and of
RBD, as well as CSF and DAT imaging parameters improves the predictive accuracy for cognitive
decline and, in the appropriate clinical context, clinicians and researchers can use the proposed
method to calculate risk of cognitive decline over two years for individuals with early with PD.
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Figure 1. Receiver Operating Characteristic Curves (ROC) for Prediction of Cognitive Impairment at 2 years
following diagnosis of Parkinson’s disease. Predictive value of a) Age only (AUC 0.68 (95% CI 0.60-0.76))
and Age with clinical variables (MDS-UPDRS motor, GDS, UPSIT and RBDSQ scores; AUC 0.76 (95% CI
0.68-0.83)), b) Age with DAT imaging (mean caudate uptake, and caudate and putaminal asymmetry; AUC
0.76 (95% CI 0.68-0.83)), c) Age with CSF Aβ1-42 (AUC 0.74 (95% CI 0.68-0.81)), d) Age with clinical
and personal variables, DAT imaging results and CSF Aβ 1-42 combined (AUC 0.80 (95% CI 0.74-0.87)). 
Table 1. Associations of MoCA change scores from baseline to two year follow up and MoCA scores at two years
Clinical markers Coefficient p-value Coefficient p-value Coefficient p-value Coefficient p-value
Age (yrs) 0.061 0.0001 0.045 0.01 -0.106 <0.0001 -0.049 0.003
Gender
Female*
Male 0.167 0.61 -0.764 0.03
Education (yrs) -0.059 0.28 0.064 0.30
Disease duration (mths) -0.034 0.13 -0.001 0.96
Motor subgroup
TD*
PIGD 0.268 -0.047
Inderminate 0.585 0.172
MoCA baseline score 0.667 <0.0001 0.572 <0.0001
GDS score 0.070 0.25 -0.063 0.35
MDS-UPDRS motor score 0.038 0.03 -0.068 0.0004
UPSIT score -0.064 0.001 -0.035 0.08 0.089 <0.0001 0.045 0.01
RBDSQ score 0.075 0.15 -0.078 0.18
Biomarkers
Apo E e4 status
No Apo e4 allel*
Heterozygous 0.740 0.658 -0.532
Homozygous 2.240 3.701 -1.047
DAT imaging
Mean putaminal uptake -0.798 0.14 1.122 0.06
Mean caudate uptake -0.641 0.02 0.574 0.06
Putaminal asymmetry -0.470 0.21 0.900 0.03
Caudate asymmetry 0.804 0.39 0.414 0.69
CSF markers (pg/ml)
Abeta1-42 -0.006 0.0002 0.004 0.02
Alphasynuclein -0.0003 0.21 0.0001 0.57
Alphasynuclein in those with haemoglobin<200ng/ml^ -0.0003 0.23 0.0001 0.68
total tau 0.019 0.03 -0.035 0.0004
Phosphorylated tau -0.003 0.83 -0.010 0.56
abeta/tau ratio -0.197 0.0002 -0.125 0.03 0.271 <0.0001 0.162 0.002
Total protein 0.015 0.07 -0.018 0.05
*Reference Category
In bold are variables included in multivariate linear regression analysis
MultivariateMultivariate
MoCA change score
0.96
0.33
Univariate
MoCA follow up score
0.57
0.03 0.01
Univariate
Table 2: Characteristics of patients with Parkinson's disease with and without Cognitive Impairment at 2 years
Patients without Cognitive Patients with Cognitive
Mean (SD) or n (%) Impairment at 2 years SD Impairment at 2 years SD p-value*
Clinical markers
N 262 52
Age (yrs) 60.18 9.926 66.12 7.833 <0.0001
Male gender (%) 170 (64.9) 38 (73.1) 0.25***
Education in years 15.65 2.598 14.62 3.748 0.06
Disease duration (mths) 6.66 6.6822 6.869 7.0968 0.84**
MoCA score 27.25 2.32 26.94 2.235 0.38
GDS score** 2 2 2 2 0.03
MDS-UPDRS motor score 20.44 8.404 23.21 10.434 0.04
UPSIT score 22.92 8.043 17.48 8.347 <0.0001
RBDSQ score 5.24 2.827 6.98 3.529 0.0003
Subgroup
TD 227(86.6%) 39 (75%)
PIGD 18 (6.9%) 8 (15.4%)
Indeterminate 17 (6.5%) 5 (9.6%) 0.11***
Genetic/Biomarkers
Apo E e4 (%) heterozygous - homozygous53 (22.4%) - 5 (2.1%) 11 (25.0%) - 1 (2.3%) 0.93***
DAT imaging
Mean putaminal uptake 0.84 0.28 0.76 0.29 0.07
Mean caudate uptake 2.07 0.54 1.77 0.55 0.0003
Putaminal asymmetry 1.54 0.42 1.40 0.35 0.03
Caudate asymmetry 1.22 0.17 1.15 0.13 0.009
CSF markers (pg/ml)
N 255 50
Abeta1-42 381.58 97.89 310.51 80.93 <0.0001
Alphasynuclein 1863.97 799.16 1753.13 688.45 0.36
Alphasynuclein in those with haemoglobin<200ng/ml^ 1819.86 737.13 1849.52 677.46 0.22
total tau 44.49 16.79 46.03 21.15 0.57
Phosphorylated tau** 12.00 7.40 11.55 10.20 0.49
Abeta1-42/tau ratio 9.44 2.97 7.84 3.06 0.0006
Total protein 42.92 18.91 48.93 23.65 0.06
*Wilcoxon, **non-parametric statistics (median, IQR, Mann-Whitney test) or *** Chi Square Tests
Significance level controlled for False Discovery Rate p<0.0167; TD; Tremor dominant; PIGD, Postural instability,
Table 3. Model for Prediction of Early Cognitive Impairment in Parkinson's Disease
Regression
Coefficient Lower Upper p-value
RBDSQ 0.123 1.131 1.001 1.277 0.048
CSFabeta1-42 -0.006 0.994 0.990 0.997 0.001
UPSIT -0.061 0.941 0.896 0.988 0.015
Mean Caudate Uptake -0.578 0.561 0.283 1.113 0.090
Age 0.051 1.053 1.005 1.103 0.029
Intercept -1.051 0.350 0.605
Bootstrapped results of multivariate logistic regression with all statistically
significant (P<0.0005) clinical and biomarker variables (including imputed missing values)
OR
95% C.I.for OR
